Are Biopsy Tracts a Concern for Seeding and Local Recurrence in Sarcomas?

• DOI: 10.1007/s11999-016-5090-y
• Publication Date: 2016-09-21T18:24:43Z
• Authors: Irene Barrientos-...; Eduardo José Orti...; José Serrano-Mont...; Daniel Bernabeu-T...; Jose Juan Pozo-Kr...
• Keywords: Open biopsy; Single Center

A biopsy is the final step in diagnosis of sarcomas. Complete resection tract traditionally has been recommended musculoskeletal oncology guidelines, as that considered potentially seeded with tumor cells. However, to our knowledge, frequency and implications contamination tract-specifically respect likelihood local recurrence-and factors affect cell seeding are not well described.We asked: (1) How often tracts contaminated pathologically detectable cells at time resection? (2) What factors, particular type (open versus percutaneous), associated tumoral seeding? (3) Is recurrence?This a retrospective study database patient data collected from single center between 2000 2013. We treated 221 patients total 27 (12%) were excluded 14 (6%) lost followup. One hundred eighty finally included analysis who either had biopsies (112) or outside institutions (68). Of those performed center, 15 (13%) open 97 (87%) percutaneous; centers, numbers 47 (69%) 21 (31%) respectively. Median followup was 40 months (range, 24-152 months). During period, we generally percutaneous standard practice for bone soft tissue sarcomas done when procedure failed provide histologic characterization. The mean age population 48 years 7-87 years); 60% male; 42% Nineteen preoperative radiotherapy 56 postoperative radiotherapy. Fifty-seven received neoadjuvant chemotherapy 73 adjuvant chemotherapy. determined what proportion by pathologic specimen; during period question, routine excise whenever possible definitive resection. Using logistic regression test Mantel-Haenszel test, compared terms site referral separately, because do assume level expertise same (our center). recurrence-free survival without using Kaplan Meier again separating referred purposes this analysis.Twenty-one 180 (12%). Twenty 62 (32%) one 118 (0.8%) core needle (odds ratio [OR], 56; 95% CI, 7-428; p < 0.001. (1%) none (0%) other centers (p = 0.047). Two 18 41(38%) (OR, 4; 1-7; 0.001). Four 74 (5%) 106 (17%) 3; 1-10; 0.023). longer (mean, 107 months; 74-141 months) than 11 1-20 0.001).Open an increased risk site, recurrence. it such complexity difficult location, influenced decision obtain biopsy. Even so, based on these results, believe higher recurrence may be caused incomplete In opinion, therapy preferred method center.Level III, therapeutic study.